Segundo, Mark S.

HRN: 23-34-50  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/12/2023
CEFTAZIDIME 1GM (VIAL)
08/12/2023
08/18/2023
IVT
175mg
Q12
Neonatal Pneumonia
Waiting Final Action 
08/12/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/12/2023
08/18/2023
IVT
55mg
Od
Neonatal Pneumonia
Waiting Final Action 
08/14/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
08/14/2023
08/21/2023
IV
175mg
Q6hours
Neonatal Pneumonia
Waiting Final Action 
08/17/2023
AZITHROMYCIN 200MG/5ML, 15ML SUSPENSION (SUSP)
08/17/2023
08/24/2023
ORAL
0.8ml
Q24
Neonatal Pneumonia
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: